Eli Lilly and Company (NYSE:LLY) Expected to Announce Quarterly Sales of $6.58 Billion


Share on StockTwits

Equities research analysts expect Eli Lilly and Company (NYSE:LLY) to announce $6.58 billion in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Eli Lilly and’s earnings, with the highest sales estimate coming in at $6.68 billion and the lowest estimate coming in at $6.47 billion. Eli Lilly and reported sales of $5.50 billion during the same quarter last year, which would suggest a positive year-over-year growth rate of 19.6%. The company is scheduled to announce its next earnings report on Thursday, July 29th.

On average, analysts expect that Eli Lilly and will report full-year sales of $27.22 billion for the current fiscal year, with estimates ranging from $27.12 billion to $27.31 billion. For the next financial year, analysts expect that the company will post sales of $28.19 billion, with estimates ranging from $27.91 billion to $28.62 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Eli Lilly and.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Monday, April 26th. The company reported $1.87 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.12 by ($0.25). The firm had revenue of $6.81 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The business’s revenue for the quarter was up 16.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.75 EPS.

A number of analysts recently issued reports on the stock. Barclays decreased their price objective on shares of Eli Lilly and from $232.00 to $227.00 and set an “overweight” rating for the company in a report on Tuesday. Bank of America raised their price objective on shares of Eli Lilly and from $195.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, January 22nd. Morgan Stanley cut their price objective on shares of Eli Lilly and from $217.00 to $207.00 and set an “overweight” rating for the company in a research report on Tuesday. Truist Securities raised their price objective on shares of Eli Lilly and from $215.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, March 22nd. Finally, Mizuho cut their price objective on shares of Eli Lilly and from $228.00 to $216.00 and set a “buy” rating for the company in a research report on Tuesday. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $200.75.

NYSE LLY traded up $2.28 during trading hours on Thursday, reaching $188.20. 3,676,930 shares of the company were exchanged, compared to its average volume of 4,089,341. Eli Lilly and has a 1 year low of $129.21 and a 1 year high of $218.00. The business’s 50 day simple moving average is $185.40 and its 200-day simple moving average is $176.26. The company has a quick ratio of 1.06, a current ratio of 1.36 and a debt-to-equity ratio of 3.27. The stock has a market capitalization of $180.48 billion, a P/E ratio of 30.75, a P/E/G ratio of 1.57 and a beta of 0.37.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 10th. Shareholders of record on Friday, May 14th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 1.81%. Eli Lilly and’s dividend payout ratio (DPR) is presently 56.29%.

In related news, major shareholder Lilly Endowment Inc sold 125,284 shares of Eli Lilly and stock in a transaction on Monday, March 8th. The shares were sold at an average price of $209.69, for a total value of $26,270,801.96. Following the sale, the insider now owns 110,422,933 shares in the company, valued at $23,154,584,820.77. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jackson P. Tai purchased 1,366 shares of the business’s stock in a transaction that occurred on Friday, April 30th. The stock was bought at an average price of $182.84 per share, for a total transaction of $249,759.44. Following the acquisition, the director now owns 60,649 shares of the company’s stock, valued at $11,089,063.16. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its holdings in Eli Lilly and by 51.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,094,613 shares of the company’s stock valued at $2,042,017,000 after acquiring an additional 4,082,728 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and during the 4th quarter valued at $1,463,293,000. Janus Henderson Group PLC boosted its holdings in shares of Eli Lilly and by 5.2% during the 4th quarter. Janus Henderson Group PLC now owns 6,124,921 shares of the company’s stock valued at $1,034,108,000 after buying an additional 302,296 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Eli Lilly and by 9.3% during the 1st quarter. Fisher Asset Management LLC now owns 5,508,308 shares of the company’s stock valued at $1,029,062,000 after buying an additional 470,518 shares in the last quarter. Finally, California Public Employees Retirement System boosted its holdings in shares of Eli Lilly and by 2.5% during the 4th quarter. California Public Employees Retirement System now owns 4,575,362 shares of the company’s stock valued at $772,504,000 after buying an additional 110,280 shares in the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More: What Is an EV Stock?

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.